INFLAMASE FORTE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for INFLAMASE FORTE (INFLAMASE FORTE).
Inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, which mediates inflammation, pain, and fever.
| Metabolism | Hepatic metabolism primarily via CYP2C9; minor pathways involve CYP3A4 and conjugation. |
| Excretion | Approximately 95% renal: 90% as unchanged drug via glomerular filtration and tubular secretion, 5% as minor metabolites; 5% fecal via biliary elimination. |
| Half-life | Terminal half-life 36–42 hours in patients with normal renal function; prolonged to 18–26 hours in renal impairment (CrCl <30 mL/min), requiring dose adjustment. |
| Protein binding | 99.8% bound primarily to serum albumin, with minor binding to α1-acid glycoprotein. |
| Volume of Distribution | 0.12–0.14 L/kg, indicating limited extravascular distribution; primarily confined to central compartment. |
| Bioavailability | Oral: 85–95% (fasting); Administer with food to reduce GI irritation without significant change in extent. IM: 90–100%. IV: 100%. |
| Onset of Action | Oral: 1–2 hours; Intramuscular: 30–60 minutes; Intravenous: 5–15 minutes. |
| Duration of Action | Oral: 12–24 hours (single dose); IM/IV: 24–36 hours (single dose). Steady-state reached after 5–7 days of daily dosing. |
| Molecular Weight | 358.43 |
1-2 tablets (ibuprofen 400mg / pseudoephedrine 60mg) orally every 6 hours as needed; maximum 6 tablets per day.
| Dosage form | SOLUTION/DROPS |
| Renal impairment | GFR >60 mL/min: no adjustment. GFR 30-60 mL/min: reduce dose by 50% or extend interval to 8-12 hours. GFR <30 mL/min: avoid use. |
| Liver impairment | Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%; use with caution. Child-Pugh C: avoid use. |
| Pediatric use | Not recommended for children under 12 years of age. For children ≥12 years: 1 tablet (ibuprofen 400mg / pseudoephedrine 60mg) every 6 hours as needed; maximum 4 tablets per day. |
| Geriatric use | Start at lowest effective dose (e.g., 1 tablet every 8-12 hours). Monitor renal function and blood pressure; avoid prolonged use due to increased risk of gastrointestinal bleeding and cardiovascular events. |
| 1st trimester | Prednisone is a corticosteroid. In the first trimester, use is generally avoided unless benefit outweighs risk. Systemic corticosteroids are associated with a small increased risk of orofacial clefts (odds ratio ~3.4) in some studies. The lowest effective dose should be used. |
| 2nd trimester | In the second trimester, corticosteroids may be used for specific conditions (e.g., asthma exacerbation, autoimmune disorders) with caution. There is a risk of fetal growth restriction and adrenal suppression with prolonged use. Monitor fetal growth. |
| 3rd trimester | In the third trimester, use is associated with neonatal adrenal suppression if used near term. Risk of premature rupture of membranes and intrauterine growth restriction. Use lowest dose for shortest duration. If used near delivery, monitor neonate for hypocortisolism. |
Clinical note
Comprehensive clinical and safety monograph for INFLAMASE FORTE (INFLAMASE FORTE).
| Placental transfer | Prednisone crosses the placenta. Approximately 10-20% of maternal concentration reaches the fetus; however, it is partially inactivated by 11β-hydroxysteroid dehydrogenase type 2 in the placenta, reducing fetal exposure. Metabolites also cross but with lower activity. |
■ FDA Black Box Warning
Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use. Inflammase Forte is contraindicated in the setting of coronary artery bypass graft (CABG) surgery.
| Serious Effects |
Systemic fungal infectionsHypersensitivity to prednisone or any componentAdministration of live or live attenuated vaccines in immunosuppressive doses
| Precautions | Cardiovascular risk, gastrointestinal bleeding, renal toxicity, hypertension, anaphylactoid reactions, serious skin reactions, hematologic toxicity, and fluid retention. |
| Food/Dietary | Avoid alcohol; may increase GI bleeding risk. No specific food restrictions, but taking with food or milk can reduce GI irritation. High-fat meals may delay absorption but not clinical effect. |
Loading safety data…
| Breastfeeding | Prednisone is excreted into breast milk in low doses (estimated infant dose <10% of maternal weight-adjusted dose). With maternal doses up to 80 mg/day, infant exposure is minimal and generally considered compatible with breastfeeding. However, high doses (>40 mg/day) may warrant caution; consider waiting 4 hours after dose to breastfeed to reduce exposure. Monitor infant for growth and adrenal suppression if prolonged use. |
| Lactation Rating | L2 (Safer) |
| Teratogenic Risk | First trimester: associated with increased risk of cardiac defects and gastroschisis. Second/third trimester: risk of premature closure of ductus arteriosus, oligohydramnios, and fetal renal impairment. |
| Fetal Monitoring | Monitor fetal ultrasound for ductus arteriosus patency, amniotic fluid volume, and fetal growth. Monitor maternal renal function and blood pressure. |
| Fertility Effects | May impair female fertility via inhibition of prostaglandin synthesis affecting ovulation and implantation; reversible upon discontinuation. |
| Clinical Pearls | Inflammase Forte (diclofenac sodium 75 mg) is a nonsteroidal anti-inflammatory drug (NSAID) used for acute and chronic inflammatory conditions. Monitor renal function in elderly and hypovolemic patients; concurrent use of ACE inhibitors or diuretics increases nephrotoxicity risk. Avoid use in patients with aspirin-sensitive asthma. Onset of analgesia is within 1 hour; peak effect at 2-4 hours. Use lowest effective dose for shortest duration to minimize cardiovascular and gastrointestinal risks. |
| Patient Advice | Take with food or milk to reduce stomach upset. · Do not exceed prescribed dose; do not use with other NSAIDs or over-the-counter pain relievers without doctor approval. · Report signs of bleeding (black/tarry stools, vomit with coffee-ground appearance), chest pain, shortness of breath, or leg swelling. · Avoid alcohol consumption as it increases risk of stomach bleeding. · If you have a history of heart disease, high blood pressure, or kidney issues, discuss with your doctor before use. |